Zylox-Tonbridge, a Hong Kong listed medical technology company specializing in neurovascular and peripheral vascular interventional solutions, has announced that it has signed a binding agreement to acquire Optimed Medizinische Instrumente GmbH, a medical device company headquartered in Germany. The transaction will be executed in multiple stages and gives Zylox-Tonbridge the option to eventually purchase one hundred percent of Optimed’s equity from its current shareholders. Optimed is engaged in the research, development, manufacturing and global distribution of medical devices used in minimally invasive therapies.
Health Technology Insights: Hyperfine Announces Regulatory Approval of the Swoop System in India
Optimed is widely recognized for its focus on vascular and endourology solutions designed for minimally invasive treatment. Over nearly thirty years, the company has built a strong international sales and service presence covering more than seventy countries. It has also established deep relationships with physicians and clinical experts across Europe and other major healthcare markets. Optimed offers one of the most extensive product ranges in the peripheral venous stenting segment, including devices specifically engineered for iliofemoral veins, the iliac bifurcation and the vena cava. Its venous stent technologies are supported by strong clinical data, including evidence from the STEVECO study, which was the first prospective randomized multicenter trial in patients with chronic deep venous obstruction and demonstrated clear improvements in patient quality of life and clinical outcomes when compared with conservative treatment approaches.
Health Technology Insights: Rona Launches First Bi-valent PCSK9-LPA siRNA for Heart Risk
This acquisition is expected to significantly advance Zylox-Tonbridge’s international growth strategy by creating an integrated platform that combines research and development, manufacturing and commercialization capabilities. By aligning the sales infrastructures of both companies and building on Optimed’s established connections with European clinicians, Zylox-Tonbridge aims to accelerate product launches and broaden its reach across global markets. The transaction is also expected to deliver operational efficiencies, supported by an expanded manufacturing presence in Germany that will help ensure consistent quality and reliable supply for customers worldwide. After completion of the deal, Zylox-Tonbridge plans to merge sales, marketing and customer support functions with Optimed to form a single global commercial organization. Rüdiger Hausherr will continue in his role as Chief Executive Officer of Optimed and will report directly to Jonathon Zhong Zhao, Chairman and Chief Executive Officer of Zylox-Tonbridge.
Dr. Jonathon Zhong Zhao stated that the agreement represents a key step in the company’s long term global vision. He noted that establishing a stronger European base will help Zylox-Tonbridge scale its operations internationally and better serve physicians and patients. He added that the combination of both companies’ product portfolios and manufacturing strengths will support the delivery of innovative, high quality and cost effective medical solutions while laying the foundation for the company’s next stage of growth.
Rüdiger Hausherr commented that Optimed has built its reputation by working closely with physicians for decades and developing trusted solutions in vascular and endourology care. He explained that changes in healthcare demands and customer expectations require a more forward looking approach. According to him, the strategic alignment with Zylox-Tonbridge brings together complementary strengths in research, manufacturing and global reach, creating a strong platform to accelerate growth and enhance value for clinicians and patients around the world.
Hans Henning von Oertzen, Founder and Managing Partner of Westlake Partners, said that since investing in Optimed, the firm has supported the expansion of its product portfolio, clinical collaborations and international presence. He described Zylox-Tonbridge as a rapidly growing global medical technology company with strong research, manufacturing and commercialization capabilities, and expressed confidence that the combination of the two organizations will unlock new opportunities and drive long term benefits for healthcare providers and patients globally.
Health Technology Insights: Wealth Enhancement to Acquire Wealth Advocates with $476 Million AUM
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
